Outcome

The study compares the effects of 1.6 ATA and 2.2 ATA hyperbaric oxygen therapy (HBOT) on traumatic brain injury (TBI) in rats. Results show that 1.6 ATA is more effective than 2.2 ATA in reducing neurological impairment by significantly lowering mRNA and protein levels of extracellular histones (H1 H2A H4) and NF-κB thereby reducing apoptosis in brain tissue and improving neurological function.

Introduction

This study explores the impact of different pressures of hyperbaric oxygen therapy (HBOT) on traumatic brain injury (TBI) in rats focusing on the expression of extracellular histones and the resulting neurological outcomes. Hyperbaric oxygen therapy involves breathing pure oxygen in a pressurized environment which can enhance healing. However finding the optimal pressure for treatment is crucial. Researchers aimed to compare the effects of 1.6 ATA (atmospheres absolute) and 2.2 ATA pressures on histone levels neural cell apoptosis and overall brain recovery after TBI. The findings revealed that 1.6 ATA significantly outperformed 2.2 ATA by reducing the levels of harmful extracellular histones such as H1 H2A and H4 and curbing neural inflammation marked by NF-κB. Consequently the lower pressure mitigated neural cell death and improved neurological function. This study underscores the potential benefits of lower pressure HBOT (1.6 ATA) in promoting brain recovery post-TBI offering valuable insights into optimizing treatment protocols for better outcomes.

Results

The study evaluated the effects of 1.6 ATA and 2.2 ATA hyperbaric oxygen therapy (HBOT) on traumatic brain injury (TBI) in rats by examining the suppression of specific extracellular histones (H1 H2A H4) and the downstream cytokine NF-κB p65. The research demonstrated that the 1.6 ATA HBO intervention was significantly more effective than the 2.2 ATA in reducing mRNA and protein levels of these extracellular histones especially within the first six hours following injury. Additionally 1.6 ATA HBO markedly lowered the expression of NF-κB p65 and NF-κB-positive staining in the peri-lesioned brain tissue at 12 and 48 hours post-TBI a reduction not observed in the 2.2 ATA group.

Moreover 1.6 ATA HBO was found to minimize extracellular histone-induced apoptosis in the peri-lesioned brain tissue showing significant effects at 24 and 48 hours post-injury a protective role not seen in the 2.2 ATA group. Functional outcomes also favored the lower pressure as rats treated with 1.6 ATA HBO demonstrated improved neurological function scores (mNSS) within 48 hours following TBI whereas the 2.2 ATA group did not show significant differences from the TBI-only group.

Overall the findings suggest that HBOT at lower pressure (1.6 ATA) is more effective in mitigating early-stage secondary brain injury by inhibiting pro-inflammatory and cytotoxic actions of extracellular histones and reducing apoptosis. These results support the notion that 1.6 ATA may be a preferable pressure protocol for treating TBI to achieve optimal therapeutic benefits.

Conclusion

In conclusion this study demonstrates that hyperbaric oxygen therapy (HBOT) at a lower pressure of 1.6 ATA is more beneficial for treating traumatic brain injuries (TBI) in rats compared to a higher pressure of 2.2 ATA. Specifically 1.6 ATA HBOT significantly reduced the levels of extracellular histones (H1 H2A H4) and NF-κB key markers associated with inflammation and cell damage whereas 2.2 ATA did not show such substantial effects. Moreover 1.6 ATA HBOT was effective in decreasing apoptosis in nerve cells and improving neurological function within the critical first 48 hours after injury. These findings suggest that lower pressure HBOT may provide a protective role by inhibiting both cytotoxic and pro-inflammatory actions of histones early after brain injury thus contributing to better outcomes in the recovery phase of TBI. As research progresses these results emphasize the importance of optimizing HBOT protocols to achieve maximum therapeutic benefits.